Cypro.
Inspired by traditional use, perfected by science.
A rationally designed herbaceutical for the management of cancer, created from the leaves of Simarouba glauca and standardised through the VedaEngine™ platform.
A rising global burden that demands gentler answers
Conventional treatments carry high costs and difficult side effects. Cypro is developed to complement existing therapy with low toxicity and multi-targeted, plant-based action.
One tree. Centuries of use. Now standardised.
Native to Florida, the Amazon, Mexico and the Caribbean, Simarouba glauca has long been used for digestive, infectious and inflammatory conditions. Cypro is prepared from its leaves, the part traditionally brewed as a decoction, tincture or tea.
Nine botanicals, one purpose
{{ active.name }}
{{ active.latin }}{{ active.desc }}
Seven reasons it stands apart
Traditional wisdom, engineered to modern standards
Every Cypro batch travels the same five-step path, a proprietary integration of ancient knowledge and rigorous science that ensures quality, efficacy and evidence at each stage.
Tested across 11 cancer cell lines
Colon, breast, lung, ovarian, melanoma, liver, bone, brain, leukemia and neuroendocrine cancers, with selectivity assessed against normal human PBMCs and mouse embryo fibroblasts.
Significant benefits in patients with solid tumors
In a study sponsored by the Centre for Integrative Medicine and Research, Simarouba Extract (Cypro) showed meaningful clinical benefit across multiple symptom domains, supported by in vivo efficacy in colon, melanoma, breast and lung cancer models.
How Cypro works on multiple fronts
A comprehensive safety package
Simple to take, thoughtfully labelled
Ready to begin with Cypro?
Affordable, accessible and non-surgical, a meaningful, plant-based option for proactive care. Place your order or speak with the CIMR care team.